logo
Joint Commission CEO Breaks Down New AI Certification

Joint Commission CEO Breaks Down New AI Certification

Newsweek26-06-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
I've settled on my word of the week: transparency. Over the last seven days, my schedule has looked like a patchwork quilt, spanning several distinct sectors of the health care industry. But from the government's roundtable on prior authorization reform to my conversation with Joint Commission CEO Dr. Jonathan Perlin (read on for more on both of those), transparency has emerged as a common thread.
Health systems and insurance companies must be transparent with one another; health systems and insurance companies must be transparent with patients. And, of course, health care companies must be transparent with their employees and customers—especially when deploying AI.
Monday through Wednesday, many of my colleagues were in sunny Sonoma, California, for Newsweek's cross-industry AI Impact Summit. Senior Reporters Lauren Giella and Katherine Fung kept eyes on the health care side of the agenda, which included speakers from Kaiser Permanente, Hospital for Special Surgery, AdventHealth and UMass Medical.
"Transparency was a big theme for AI adoption in health care—not only when dealing with medical records and personal data, but also for why and how organizations are implementing automation tools," Giella wrote.
Dr. Allen Chang, ACMIO at UMass Medical, warned the audience not to neglect employees' concerns about losing jobs to AI, nodding to last year's strike by the California Nurses Association.
"A lot of us say that we're not going to be replaced by AI, we want to believe that, but in medicine, we can't just invoke this and expect that to address the underlying drivers as to why people are asking about this," Chang said on Tuesday's health care panel.
What could those underlying drivers be? I found some clues in Wolters Kluwer Health's new generative AI readiness report, released at the start of the month. Their survey of health care stakeholders found that 76 percent cite "reducing clinician burnout" as a major priority, and 85 percent say "recruiting/retaining nursing staff" is top of mind.
But only 45 percent of nurses responded "yes" when asked if generative AI can reduce clinician burnout.
I asked Dr. Peter Bonis, chief medical officer at Wolters Kluwer Health, to help me make sense of that gap—or "disconnect," as he called it.
"Our survey is indicating that there's an opportunity to work with allied health professionals and clinicians to deeply understand their needs and where some of these technologies can help; to have them on participatory boards as they themselves get educated on what these tools can do; and to select these tools so that they are optimizing their workflows, and they have agency in this process," he said.
I've been reporting on a lot of AI-related "disconnects" lately, both within health systems' AI deployment efforts and in external communications with vendors. I asked Bonis: Do these lapses indicate that we're taking the wrong approach to AI deployment in the health care industry?
He told me that this isn't exclusive to the health care industry, and that every business is wrestling with the same sort of issues. (Phew.) But, he acknowledged, health care is a high-stakes game, and it's important to deploy AI safely (and transparently) for the benefit of employees, patient care and overall health equity.
He believes health systems will succeed if they focus on patient care and bolster that foundation with sound operations and a successful business model.
"The fusion of those two directives is what creates a future-ready health care system that understands how to use these advanced technologies to advance their operations—to do that thoughtfully—and then to have a coherent pathway to start to use these tools to advance that higher stakes domain," Bonis said, "and that's the journey that we're on."
I also spoke with Dr. Perlin, head of the Joint Commission, about that journey to a "coherent" AI pathway. Read on to the Pulse Check section to see what he said.
Essential Reading
Aiming to improve the prior authorization process, HHS Secretary Robert F. Kennedy, Jr., and CMS Administrator Dr. Mehmet Oz hosted a roundtable of health insurance executives and stakeholders on Monday.
on Monday. Attendees agreed to six reforms: (1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials.
(1) standardizing electronic prior auth submissions, (2) reducing the volume of services that require prior auth, (3) honoring existing approvals during insurance transitions, (4) improving transparency and communication around decisions, (5) implementing real-time approvals for most requests by 2027 and (6) ensuring medical professionals review all denials.
These companies were included in the discussion: Aetna, AHIP, Blue Cross Blue Shield Association, CareFirst BlueCross BlueShield, Centene Corporation, The Cigna Group, Elevance Health, GuideWell, Highmark Health, Humana, Kaiser Permanente and UnitedHealthcare. Together, they represent about 75 percent of Americans with commercial or Medicare Advantage plans.
The Lown Institute has released its highly anticipated index of America's Most Socially Responsible Hospitals. This year's honor roll comes at a critical time, as hospitals work to maintain equitable care amid potential Medicaid cuts, rising costs and ongoing workforce challenges. Duke Regional Hospital topped this year's acute care ranking, marking its fifth year on the list.
Eli Lilly's once-weekly insulin efsitora displayed promising results in Phase 3 clinical trials, reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections. Diabetes is becoming more prevalent in the United States , affecting nearly 15 percent of adults. By the end of 2025, Eli Lilly plans to submit the drug to global regulatory agencies for the treatment of Type 2 diabetes.
reducing A1C and meeting safety standards for adults with Type 2 diabetes, according to detailed datapublished by the company this week. The new drug hopes to simplify diabetes management by reducing the frequency of insulin injections.
Artisight, the NVIDIA-backed health tech company specializing in AI-powered "smart hospital" infrastructure, announced a $40 million investment from a dozen health systems. It's an unprecedented level of support from some of the nation's largest, most forefront integrated systems and academic medical centers. (The list of names was reviewed by Newsweek but is not being released to the public at this time.)
Pulse Check
Dr. Jonathan Perlin is president and CEO of the Joint Commission.
Dr. Jonathan Perlin is president and CEO of the Joint Commission.
Joint Commission
If you've been paying attention to the news lately, you may have had the same question that I did: What on earth is going on at the Joint Commission?The independent health care accreditation and certification organization has launched a couple high-profile, high-tech partnerships in recent weeks. First, it announced a long-term relationship with Palantir, intending to use the company's AI platform to streamline accreditation/certification processes. Then, it joined forces with the Coalition for Health AI to establish a "suite" of AI best practices playbooks and a new certification for hospitals. Now, if you work at a hospital, you likely live by the Joint Commission's standards. That's why I called Dr. Jonathan Perlin, president and CEO of The Joint Commission, last Friday. There was a bit of "geeking out about AI," as Perlin put it. But mostly, we discussed the recent CHAI partnership—and what it could mean for quality/safety standards and hospital certifications. Editor's Note: Responses are lightly edited for length and clarity.
AI is so different from other components used to assess quality. Each health system uses it in a unique way, and applications vary between hospitals, departments and even patient populations. "Good AI" can be tough to quantify. How do you plan to create a standard with this new certification program? CHAI's lane is really the technology itself, and ours is the organization's governance process for the responsible use of that. You may have seen our Responsible Use of Health Data Certification that has six attributes, and this is really an extension of that. What we anticipate—and this is a work in progress—is that building from the Responsible Use of Health Data [Certification], there'd be requirements for de-identification or privacy that could be data controls for security. There should be some mechanism for transparency with patients. Most importantly, there would be like an oversight or governance structure that addresses the algorithm's or the AI's performance. The notion is that an organization can look to CHAI and to the market to identify an AI tool, but it has to have an active and ongoing governance process to look at the performance of that tool in their environment. To give an example, I think there are three essential components. One is technical: Is [the tool] valid and reliable in a sort of mathematical sense? Second, is it valid and reliable clinically? Does it present the right clinical information? And third, is it valid and reliable in a demographic sense, that you're not applying an AI trained specifically for detection of sepsis in adults to children. To make that clear, if CHAI's lane is really the external performance of the algorithm and the assurance aspects outside of health care, the way we do this [new certification] is not specifically directed at the certification of the AI tool, but the certification of process for the organization's own governance and oversight of the use responsible use of that AI tool.
Will this certification assess tools that health systems developed internally, vendor tools that they deploy, or a combination of both? What else will you be looking at within each hospital's AI ecosystem? We anticipate that the certification, which would be given to health care organizations, would be based on the governance structure and the oversight structure I described [above]. We expect it would be applied both to homegrown and off-the-shelf technologies. Our focus is on continuous governance. Let me give an example that's literally closer to home. We just finished a renovation [at my house], and we had an electrical inspection after the work was completed. The wiring of the house is not going to change over time, but the wiring of AI, if it's retrained, if it drifts, etc., may change over time—so the organization needs to have a mechanism for periodic review of the performance of its "electrical system," to use the analogy, not just at inception, but periodically, or frankly, for the life of the use of that technology.
Any advice for health systems that are currently building up their AI governance structures, to ensure they're on the right path ahead of the Joint Commission and CHAI's certification?
Take a look at our Responsible Use of Health Data Certification , because it really provides insight into the concepts of governance as the regulatory frameworks are emerging. Despite the fact that device drug approvals are static, they are viewing the use of device (good outcomes or bad) as the responsibility of the clinicians and health care organizations that use those. Having come from operations and large systems myself, it's really important to have a set of externally validated standards that demonstrate what "good" looks like for responsible governance and oversight. I think organizations like ours are hugely excited about the potential, but we want to set up common standards to assure that we realize that potential responsibly.
If you liked this sneak peek, remember to check out next week's edition, which will include more of my interview with Perlin.
C-Suite Shuffles
Joseph Impicciche is retiring as CEO of Ascension, after six years at the helm of the St. Louis-based system. Eduardo Conrado, the health system's current president, will become its new CEO on January 1, 2026. Conrado was named to Ascension's executive team in 2018, after five years on its board of directors. Throughout his tenure, he has also served as the system's chief digital officer and chief strategy and innovation officer.
The Medical University of South Carolina (MUSC) has selected Dr. John Marymont as its next provost and executive vice president for academic affairs. Currently, he serves as vice president for medical affairs and dean of the medical college at the University of South Alabama.
Lovelace Health System is undergoing its fourth CEO change since 2022, the Albuquerque Journal reported. President and CEO Troy Greer resigned last week after two years in the role. The health system—one of the largest in New Mexico—declined to comment on his exit.
Executive Edge
Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals.
Dr. Leigh Vinocur is a thought leader on stress management amongst health care professionals.
Dr. Leigh Vinocur
Dr. Leigh Vinocur tells me that she considers herself a "lifelong learner." She's spent her career learning different elements of medicine, starting as a urology resident, becoming a board-certified emergency physician and serving as chief medical director for a major health system, overseeing more than 100 providers in the mid-Atlantic region. Now, she is the medical director of a men's health clinic and works part-time in clinical trials at a nutraceutical company. But throughout her working life, Vinocur has also learned a great deal about stress. After leaving her big-box health care role, she dealt with a "corporate medicine hangover." On July 12, she's releasing a book about her journey: Never Let Them See You Sweat: How Science Can Help Us Harness Stress for Success. This week, I connected with Vinocur to learn what her research—and personal experiences—taught her about stress in the health care setting. Here's what she told me: Editor's Note: Responses are lightly edited for length and clarity. "Today, in this political climate, we're seeing changes to health care, erosion of public health. It's making it even more difficult [to work in health care leadership]. There were always issues as a physician, fighting with insurance companies—but as physician executives, it's that kind of double bind that they're in, because they're caregivers, but they're administrators. They have rules they're enforcing, fiscal and institutional constraints, but they have to put their patients first, too. And it's stressful.
"Not all stress is always horrible and bad. It gets you to your tiptop performance, you know. Stress was an evolutionary development and advantage to keep us safe. If you were out there being chased by a predator, all those reactions from the hypothalamus, the pituitary, the adrenal release the cascade of hormones for that fight or flight. Whether you're a runner in the Olympics standing in the blocks, or whether you're an ER doctor waiting in the resuscitation room for those accident victims to come in, that little boost of stress gets you at your top performance. It's just this continued stress that is so challenging.
"I tell executive leaders that they need some buffer in between meetings. You need to create little micro-breaks during the day that are just for you to calm down. Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing).
Whether that's meditation (there are apps on our watches and our phones), deep breathing (like box breathing, where you inhale through your nose for four seconds, hold it for four seconds and exhale for four seconds through your mouth), or leadership mentoring (where you have open dialogue and create a safe space to talk about some of the ethical dilemmas you may be facing). "All throughout the book, there are discussions on things you can do in nature, like 'forest bathing.' Study after study says that if you can get to a green space, like a park, that can lower your blood pressure. Just being out in nature, getting outside—you don't even have to exercise—can be a great relief."
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials
Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Yahoo

timean hour ago

  • Yahoo

Google DeepMind has grand ambitions to ‘cure all diseases' with AI. Now, it's gearing up for its first human trials

Alphabet's Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind's AlphaFold breakthrough, the company is pairing cutting-edge AI with pharma veterans to design medicines faster, cheaper, and more accurately. Alphabet's secretive drug discovery arm, Isomorphic Labs, is getting ready to start testing its AI-designed drugs in humans, Colin Murdoch, Isomorphic Labs president and Google DeepMind's chief business officer, told Fortune. 'There are people sitting in our office in King's Cross, London, working, and collaborating with AI to design drugs for cancer,' Murdoch said during an interview in Paris. 'That's happening right now.' After years in development, Murdoch says human clinical trials for Isomorphic's AI-assisted drugs are finally in sight. 'The next big milestone is actually going out to clinical trials, starting to put these things into human beings,' he said. 'We're staffing up now. We're getting very close.' The company, which was spun out of DeepMind in 2021, was born from one of DeepMind's most celebrated breakthroughs, AlphaFold, an AI system capable of predicting protein structures with a high level of accuracy. Interactions of AlphaFold progressed from being able to accurately predict individual protein structures to modeling how proteins interact with other molecules like DNA and drugs. These leaps made it far more useful for drug discovery, helping researchers design medicines faster and more precisely, turning the tool into a launchpad for a much larger ambition. 'This was the inspiration for Isomorphic Labs,' Murdoch said of AlphaFold. 'It really demonstrates that we could do something very foundational in AI that could help unlock drug discovery.' In 2024, the same year it released AlphaFold 3, Isomorphic signed major research collaborations with pharma companies Novartis and Eli Lilly. A year later, in April 2025, Isomorphic Labs raised $600 million in its first-ever external funding round, led by Thrive Capital. The deals are part of Isomorphic's plan to build a 'world-class drug design engine,' a system that combines machine learning researchers with pharma veterans to design new medicines faster, more cheaply, and with a higher chance of success. As part of the deals with major pharma players, Isomorphic supports existing drug programs, but it also designs its own internal drug candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials. 'We identify an unmet need, and we start our own drug design programs. We develop those, put them into human clinical trials… we haven't got that yet, but we're making good progress,' he said. Today, pharma companies often spend millions attempting to bring a single drug to market, sometimes with just a 10% chance of success once trials begin. Murdoch believes Isomorphic's tech could radically improve those odds. 'We're trying to do all these things: speed them up, reduce the cost, but also really improve the chance that we can be successful,' he says. He wants to harness AlphaFold's technology to get to a point where researchers have 100% conviction that the drugs they are developing are going to work in human trials. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease,' Murdoch said. 'All powered by these amazing AI tools.' This story was originally featured on

Woman Has Sore Throat While Pregnant, Then Comes Shock Diagnosis
Woman Has Sore Throat While Pregnant, Then Comes Shock Diagnosis

Newsweek

time4 hours ago

  • Newsweek

Woman Has Sore Throat While Pregnant, Then Comes Shock Diagnosis

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. After finding out she was pregnant in November 2022, Mariana Bom should have been filled with excitement and anticipation. But instead, she couldn't shake the feeling there was something seriously wrong. In the first trimester, Bom, 25, noticed multiple white patches and an ulcer on the back of her tongue. Shortly after, Bom, of Germany, also developed a sore throat and earache too. She told Newsweek that she wondered if they were side effects of the COVID vaccine at the time, but doctors "always dismissed this theory." But when she noticed a small blister at the back of her tongue that hadn't gone away for two weeks, Bom grew concerned. She visited an ear, nose and throat (ENT) specialist to get a second opinion Bom said: "The ENT told me it was nothing serious, that it would go away, and there was no sign of danger. A month later, I went back, and they said it could be due to pregnancy as dental issues or oral thrush are common." Mariana Bom laying in a hospital bed after her diagnosis. Mariana Bom laying in a hospital bed after her diagnosis. @mariana___1999 / TikTok The mouth ulcer continued to grow and that area of her mouth became really swollen. The more it pressed against her teeth, simple acts like eating and talking became excruciating. As the weeks went by and her symptoms persisted, Bom took matters into her own hands. She did some research and was horrified to learn that her symptoms aligned with tongue cancer. "One evening, I went to the emergency room. My belly was already visible by then and I told them that I suspected tongue cancer. At the ER reception, I was laughed at because I was too 'young to have cancer' in their view," Bom said. "In the treatment room, the doctor dismissed me and told me to put baking soda on my tongue and that it would go away." That wasn't good enough for Bom, who decided to see another ENT two weeks later. She was determined to get answers and needed to be heard. The next ENT decided to do a biopsy and check for any signs of malignancy. Just a week later, everything changed. "That's when I got the call—it was an aggressive tongue carcinoma," Bom said. Cancer is devastating for anyone, but being pregnant made it even more complicated. Bom hadn't even told her family she was pregnant because it was still so early. But now she had to tell them that not only was she expecting, but she had cancer too. Her mom, who had battled cervical cancer in 2019, instantly took her daughter's hand and supported her. "Since I was pregnant, our biggest concern was the baby. Would it have to come early? What were the options?" Bom told Newsweek. "After many discussions between the specialist doctors, we decided, for the sake of my baby and my health, that I would undergo surgery while pregnant to remove as much of the tumor as possible." Surgery to remove the tumor lasted between five and seven hours. The cancer had already spread to the lymph nodes in her neck, so they too were removed. Bom's recovery involved spending two weeks in hospital, unable to eat or speak, and with drains coming out of her neck. It was a living nightmare, and she didn't know if she'd ever feel the same. Mariana Bom while pregnant in 2022. Mariana Bom while pregnant in 2022. @mariana___1999 / TikTok "After two weeks, the ENT specialists and the OB-GYNs discussed whether my daughter should be delivered early so I could start radiation therapy—to be sure we destroyed any remaining cancer cells. Eventually, they decided to deliver her one month after my surgery via C-section," Bom continued. Bom's daughter was delivered at 30 weeks and immediately taken to the neonatal intensive care unit (NICU). She was placed on a ventilator as she was struggling to breathe and given a feeding tube. Just a few weeks after welcoming her daughter, Bom began radiation. For the next eight weeks, she'd go to the hospital for treatment and then visit her daughter in the NICU after. Her battle was certainly not over because the radiation side effects were so intense. It was "nearly impossible" to eat anything, she lost her sense of taste and felt exhausted. "For the first few weeks, I could only consume liquid. I lost a lot of weight, and I felt extreme fatigue. I think it was a combination of postpartum exhaustion and the toll that the cancer treatment took on my body," she said. Thankfully, Bom and her daughter are doing much better now. While there are some lasting effects, Bom is glad to have her life and to still be here for her family. She still gets inflammation in her mouth frequently, and on some occasions, it feels as though her body has "been beaten up." While healing, Bom has documented her experience on TikTok (@mariana___1999) to raise awareness and encourage others to seek answers. She didn't even know tongue cancer existed before her diagnosis, and what little information she found online left her without hope. Now, she wants to be a beacon of light for others. For anyone experiencing symptoms, Bom urges them to listen to their body and push for answers. "You always hear about common cancers, but I had never heard of tongue cancer," Bom said. "The only thing that kept me going was thinking about my children and my husband. Without them, I don't think I would've gotten through it. I wanted to show that there are different outcomes and it's possible to survive." Is there a health issue that's worrying you? Let us know via health@ We can ask experts for advice, and your story could be featured on Newsweek.

New AI-Powered Treatment Planning App Developed by JSE
New AI-Powered Treatment Planning App Developed by JSE

Associated Press

time7 hours ago

  • Associated Press

New AI-Powered Treatment Planning App Developed by JSE

The app combines artificial intelligence, voice recognition, & rich text editing to assist healthcare providers in creating & managing patient treatment plans. CHESAPEAKE, VA, UNITED STATES, July 6, 2025 / / -- Key Features AI-Powered Clinical Support The module integrates ChatGPT technology to assist healthcare providers in creating treatment plans. The AI system analyzes patient data and clinical observations to suggest interventions, goals, and timelines, while maintaining provider oversight and customization capabilities. Voice-to-Text Integration Healthcare professionals can dictate treatment plans using integrated Web Speech API technology. The voice recognition system includes: - Real-time speech-to-text conversion with visual feedback - Automatic 30-second recording sessions - Integration with rich text editing capabilities - Support for medical terminology Rich Text Documentation Built on CKEditor 4 technology, the module provides healthcare providers with: - Formatting toolbar for medical documentation - Text editing capabilities for clinical notes - Voice controls integrated with rich text formatting Security and Integration Features API Management The module implements security practices including: - Encrypted API key storage in database - Backend integration without hardcoded credentials - Error handling and validation - HIPAA-compliant data handling Clinical Workflow Integration - Encounter-based treatment plan association for billing and documentation - Version control system for treatment plan revisions - Multi-stage approval workflow from draft to finalized status - Condition-specific treatment templates - PDF export functionality - API usage tracking by provider Technical Implementation The module features: - Separation of concerns across Controllers, Services, and Models - Database schema supporting versioning and audit trails - Event-driven architecture - Error handling and logging capabilities - Scalable design for healthcare environments Industry Applications The module addresses documentation efficiency, clinical decision support, and workflow integration in healthcare settings. Features include: - The module integrate ChatGPT for treatment planning - Voice-to-text designed for medical documentation - Security model for AI API integration in healthcare - Rich text editing optimized for clinical workflows Availability The Treatment Planning App is now available for use by behavioral healthcare providers. The module's architecture supports deployment and maintenance while providing reliability and security for healthcare organizations. Healthcare organizations can access the module through contacting Mind Therapy Works at or 1-833-693-1972. Technical Specifications The module leverages: - OpenAI's ChatGPT for treatment plan generation - Web Speech API for voice input - CKEditor 4 for rich text editing - PHP/Twig architecture for backend processing - Security frameworks for healthcare data protection --- Media Contact: Sherwin Gaddis, Technical Director Mind Therapy Works Phone: 1-833-693-1972 Email: [email protected] Sherwin E Gaddis Affordable Custom EHR +1 757-328-2736 email us here Visit us on social media: YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store